JRSM > Volume 101, Number 3 > Pp. 125-132

This Article Full Text Full Text (PDF) Send a Quick Comment Alert me when this article is cited Alert me when Quick Comments are posted Alert me if a correction is posted Services Email this article to a friend Related articles in JRSM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wilson, P. M Articles by Watt, I. S Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage

Paul M Wilson Research Fellow in Dissemination  ¹ Alison M Booth Research Fellow in Dissemination  ¹ Alison Eastwood Senior Research Fellow  ²   Ian S Watt Professor of Primary and Community Care  ³

¹ Centre for Reviews and Dissemination, University of York, UK
² Centre for Reviews and Dissemination, University of York, UK
³ Department of Health Sciences, University of York, UK

Correspondence to: Paul M Wilson pmw7{at}york.ac.uk

Objective To explore and critically describe the content and main narratives of UK national daily newspaper coverage of trastuzumab (Herceptin®).

Design We used the NewsBank database to search eight national daily newspapers, and their Sunday equivalents, retrospectively from 19 February 2006 back to the earliest mention of trastuzumab or Herceptin (19 May 1998).

Setting UK national newspapers.

Main outcome measures To be eligible for inclusion, articles had to contain at least three sentences about trastuzumab. Articles that focused on the financial performance of companies associated with the drug were excluded from the analysis. For each included article, we extracted bibliographic details and data, and independently rated the reporting slant towards trastuzumab and, where relevant, the reporting slant towards access to treatment.

Results We identified 361 articles that met the study inclusion criteria. The proprietary name of Herceptin was always used, with only eight articles mentioning the generic alternative. 294/361 included articles (81.5%) were rated as being positive towards trastuzumab, the remainder rated as neutral. Access to trastuzumab treatment was the main narrative running across included articles and reports of individual patients seeking treatment featured prominently throughout. In 208/361 of included articles (57%) the reporting slant towards access to trastuzumab treatment was rated as negative. 178/361 of included articles (49.3%) mentioned licensing, but rarely mentioned that licensing processes can only occur when the manufacturer applies for a licence. Only a minority of articles mentioned that the drug had to be licensed before it could be subject to the NICE approval process.

Conclusions Newspaper coverage of trastuzumab has been characterized by uncritical reporting. Journalists (and consumers) should be more questioning when confronted with information about new drugs and of the motives of those who seek to set the news agenda.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related articles in JRSM:

Doctors: the media’s favourite worst nightmare

Kamran Abbasi
JRSM 2008 101: 99. [Full Text]  

This article has been cited by other articles:

				R E Ferner and S. E McDowell A model for NICE in the US BMJ, June 3, 2009; 338(jun03_2): b2221 - b2221. [Full Text]